Nasdaq-listed atai Life Sciences, a Germany-based clinical-stage biopharmaceutical company focused on treating mental health disorders, has priced a registered underwritten offering of 23,725,000 common shares, at a price of US$5.48…
Germany: atai raises US$130m from share offering as US FDA grants BTD to BPL-003
…
…






